NR3C1 and hypertensive disorder: Mifepristone is an oral non-selective GR antagonist, officially approved by EMA in February 2012 for the treatment of CS of any cause, if the patient has glucose intolerance and hypertension, or both, and cannot undergo or refuses surgery [42,68].